Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H7O2.Na |
Molecular Weight | 158.1297 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[O-]C(=O)CC1=CC=CC=C1
InChI
InChIKey=HZOREEUASZHZBI-UHFFFAOYSA-M
InChI=1S/C8H8O2.Na/c9-8(10)6-7-4-2-1-3-5-7;/h1-5H,6H2,(H,9,10);/q;+1/p-1
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C8H7O2 |
Molecular Weight | 135.14 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB09269Curator's Comment: description was created based on several sources, including:
https://clinicaltrials.gov/ct2/show/NCT00003241?term=Phenylacetic+acid&rank=3
https://en.wikipedia.org/wiki/Phenylacetic_acid
Sources: http://www.drugbank.ca/drugs/DB09269
Curator's Comment: description was created based on several sources, including:
https://clinicaltrials.gov/ct2/show/NCT00003241?term=Phenylacetic+acid&rank=3
https://en.wikipedia.org/wiki/Phenylacetic_acid
Phenylacetic acid (abr. PAA and synonyms are: α-toluic acid, benzeneacetic acid, alpha tolylic acid, 2-phenylacetic acid, β-phenylacetic acid) is an organic compound containing a phenyl functional group and acarboxylic acid functional group. Because it is used in the illicit production of phenylacetone (used in the manufacture of substituted amphetamines), it is subject to controls in countries including the United States and China Phenylacetic acid is used in some perfumes, possessing a honey-like odor in low concentrations, and is also used in penicillin G production. It is also employed to treat type II hyperammonemia to help reduce the amounts of ammonia in a patient's bloodstream by forming phenylacetyl-CoA, which then reacts with nitrogen-rich glutamine to form phenylacetylglutamine. This compound is then secreted by the patient's body. In Phase 2 of clinical research it investigated in the treatment of Brain and Central Nervous System Tumors.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=935645
Curator's Comment: Known to be CNS penetrant in cat. Human data not available.
Labeled phenylacetic acid (14C-PAA) penetrates blood-cerebrospinal fluid (CSF) barrier in cats only under a high gradient of concentration
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | AMMONUL Approved UseSodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. Launch Date1.10851195E12 |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2225 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15050977/ |
3.75 g/m² single, intravenous dose: 3.75 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: SODIUM BENZOATE |
PHENYLACETIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
3022 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15050977/ |
5.5 g/m² single, intravenous dose: 5.5 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: SODIUM BENZOATE |
PHENYLACETIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
281 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15050977/ |
3.75 g/m² single, intravenous dose: 3.75 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: SODIUM BENZOATE |
PHENYLACETYLGLUTAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
15004 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15050977/ |
3.75 g/m² single, intravenous dose: 3.75 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: SODIUM BENZOATE |
PHENYLACETIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
28156 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15050977/ |
5.5 g/m² single, intravenous dose: 5.5 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: SODIUM BENZOATE |
PHENYLACETIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2047 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15050977/ |
3.75 g/m² single, intravenous dose: 3.75 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: SODIUM BENZOATE |
PHENYLACETYLGLUTAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.44% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8946671/ |
SODIUM PHENYLACETATE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Disc. AE: Metabolic acidosis, Injection site reactions... AEs leading to discontinuation/dose reduction: Metabolic acidosis (< 1%) Sources: Page: p.11Injection site reactions (< 1%) Bradycardia (0.32%) Abdominal distension (0.32%) Injection site extravasation (0.32%) Hemorrhage injection site (0.32%) Blister (0.32%) Subdural hematoma (0.32%) Hyperammonemia (0.32%) Hypoglycemia (0.32%) Clonus (0.32%) Coma (0.32%) Increased intracranial pressure (0.32%) Hypercapnia (0.32%) Kussmaul respiration (0.32%) Respiratory distress (0.32%) Respiratory failure (0.32%) Pruritis (0.32%) Maculo-papular rash (0.32%) |
300 mg/kg 1 times / day multiple, intravenous (max) Recommended Dose: 300 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 300 mg/kg, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.8Arginine HCl, i.v(200-600 mg/kg) |
unhealthy Health Status: unhealthy Condition: Cancer Sources: Page: p.8 |
Other AEs: Neurotoxicity... Other AEs: Neurotoxicity Sources: Page: p.8 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abdominal distension | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Blister | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Bradycardia | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Clonus | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Coma | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Hemorrhage injection site | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Hyperammonemia | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Hypercapnia | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Hypoglycemia | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Increased intracranial pressure | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Injection site extravasation | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Kussmaul respiration | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Maculo-papular rash | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Pruritis | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Respiratory distress | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Respiratory failure | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Subdural hematoma | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Injection site reactions | < 1% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Metabolic acidosis | < 1% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Neurotoxicity | 300 mg/kg 1 times / day multiple, intravenous (max) Recommended Dose: 300 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 300 mg/kg, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.8Arginine HCl, i.v(200-600 mg/kg) |
unhealthy Health Status: unhealthy Condition: Cancer Sources: Page: p.8 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203284Orig1s000PharmR.pdf#page=26 Page: 26.0 |
PubMed
Title | Date | PubMed |
---|---|---|
The glutathione metabolism of the beta-lactam producer filamentous fungus Penicillium chrysogenum. | 2001 |
|
Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. | 2001 |
|
Penicillin productivity and glutathione-dependent detoxification of phenylacetic and phenoxyacetic acids in Penicillium chrysogenum. | 2001 |
|
Directed control of electroosmotic flow in nonaqueous electrolytes using poly(ethylene glycol) coated capillaries. | 2001 |
|
Prostate cancer prevention strategies using antiproliferative or differentiating agents. | 2001 Apr |
|
Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. | 2001 Apr |
|
Magnetic resonance pharmacoangiography to detect and predict chemotherapy delivery to solid tumors. | 2001 Apr 1 |
|
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. | 2001 Aug |
|
Expression and purification of extracellular penicillin G acylase in Bacillus subtilis. | 2001 Feb |
|
[Determination of degraded products of penicillin by high performance liquid chromatography]. | 2001 Jan |
|
Current strategies for the management of neonatal urea cycle disorders. | 2001 Jan |
|
[Determination of organic acids in cigarette smoke]. | 2001 Jul |
|
Aroma-active components of nonfat dry milk. | 2001 Jun |
|
Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. | 2001 Jun |
|
Decrease of breast cancer cell invasiveness by sodium phenylacetate (NaPa) is associated with an increased expression of adhesive molecules. | 2001 Mar 23 |
|
Could 99mTc-MIBI be used to visualize the apoptotic MCF7 human breast cancer cells? | 2001 May |
|
Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor gamma. | 2001 May 15 |
|
Phenylethylamine, a possible link to the antidepressant effects of exercise? | 2001 Oct |
|
Inhibitors of histone deacetylase as new anticancer agents. | 2001 Oct |
|
Oxygen dependency of monoamine oxidase activity in the intact lung. | 2001 Oct |
|
Clean-chemistry synthesis of 2-tetralones in a single-stage acylation-cycloalkylation process. | 2001 Oct 19 |
|
A chemostat culture as a tool for the improvement of a recombinant E. coli strain over-producing penicillin G acylase. | 2001 Oct 5 |
|
Inhibition of estrogen-dependent breast cell responses with phenylacetate. | 2001 Sep 1 |
|
Evaluation of strains derived from Escherichia coli W as hosts for the expression of penicillin G-acylase-encoding gene cloned on the recombinant plasmid pKA18. | 2002 |
|
Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. | 2002 Apr |
|
The role of hydrophobic active-site residues in substrate specificity and acyl transfer activity of penicillin acylase. | 2002 Apr |
|
Effects of cryopreservation and phenylacetate on biological characters of adherent LAK cells from patients with hepatocellular carcinoma. | 2002 Apr |
|
Fermentation of cottonseed and other feedstuffs in cattle rumen fluid. | 2002 Apr 10 |
|
Application of molecular genetics to the diagnosis of lymphoid-rich effusions: study of 95 cases with concomitant immunophenotyping. | 2002 Aug |
|
Identification of bacteria in drinking and purified water during the monitoring of a typical water purification system. | 2002 Aug 15 |
|
Neonatal presentation of ventricular tachycardia and a Reye-like syndrome episode associated with disturbed mitochondrial energy metabolism. | 2002 Dec 30 |
|
4-Fluoro-N-butylphenylacetamide: a synthetic phenylacetate derivative that upregulates Bcl-X(S), activates caspase cascade and induces apoptosis in human squamous lung cancer CH27 cells. | 2002 Dec 5 |
|
Pheromone components of the wheat stem sawfly: identification, electrophysiology, and field bioassay. | 2002 Feb |
|
Investigations into tumor accumulation and peroxisome proliferator activated receptor binding by F-18 and C-11 fatty acids. | 2002 Feb |
|
Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides. | 2002 Feb 25 |
|
Monitoring of enzymatic hydrolysis of penicillin G by pyrolysis-negative ion mass spectrometry. | 2002 Jul 1 |
|
Immunosuppressant-like effects of phenylbutyrate on growth inhibition of Saccharomyces cerevisiae. | 2002 Jun |
|
[Up regulation of phenylacetate to glioma homeobox gene expression]. | 2002 Mar |
|
Emended descriptions of the genus Micrococcus, Micrococcus luteus (Cohn 1872) and Micrococcus lylae (Kloos et al. 1974). | 2002 Mar |
|
Induction and repression of the sty operon in Pseudomonas putida CA-3 during growth on phenylacetic acid under organic and inorganic nutrient-limiting continuous culture conditions. | 2002 Mar 5 |
|
Paraoxonase Gln-Arg(192) and Leu-Met(55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. | 2002 May |
|
Identification of phenyldecanoic acid as a constituent of triacylglycerols and wax ester produced by Rhodococcus opacus PD630. | 2002 May |
|
Metabolic physiology of aroma-producing Kluyveromyces marxianus. | 2002 Nov |
|
Arginine 165/arginine 277 pair in (S)-mandelate dehydrogenase from Pseudomonas putida: role in catalysis and substrate binding. | 2002 Oct 15 |
|
Successful treatment of severe hyperammonemia using sodium phenylacetate powder prepared in hospital pharmacy. | 2002 Sep |
|
[Treatment of methicillin-resistant Staphylococcus aureus (MRSA) as part of biosurgical management of a chronic leg ulcer]. | 2002 Sep |
|
Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response. | 2003 Apr |
|
Paraoxonase and susceptibility to organophosphorus poisoning in farmers dipping sheep. | 2003 Feb |
|
Structure-activity relationships of novel anti-malarial agents: part 5. N-(4-acylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides. | 2003 Feb 10 |
|
Environmental effects caused by olive mill wastewaters: toxicity comparison of low-molecular-weight phenol components. | 2003 Feb 12 |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:28:54 UTC 2023
by
admin
on
Wed Jul 05 23:28:54 UTC 2023
|
Record UNII |
48N6U1781G
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
197804
Created by
admin on Wed Jul 05 23:28:54 UTC 2023 , Edited by admin on Wed Jul 05 23:28:54 UTC 2023
|
||
|
DEA NO. |
8791
Created by
admin on Wed Jul 05 23:28:54 UTC 2023 , Edited by admin on Wed Jul 05 23:28:54 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/19/2166
Created by
admin on Wed Jul 05 23:28:54 UTC 2023 , Edited by admin on Wed Jul 05 23:28:54 UTC 2023
|
||
|
NCI_THESAURUS |
C78275
Created by
admin on Wed Jul 05 23:28:54 UTC 2023 , Edited by admin on Wed Jul 05 23:28:54 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID8059427
Created by
admin on Wed Jul 05 23:28:54 UTC 2023 , Edited by admin on Wed Jul 05 23:28:54 UTC 2023
|
PRIMARY | |||
|
48N6U1781G
Created by
admin on Wed Jul 05 23:28:54 UTC 2023 , Edited by admin on Wed Jul 05 23:28:54 UTC 2023
|
PRIMARY | |||
|
56510
Created by
admin on Wed Jul 05 23:28:54 UTC 2023 , Edited by admin on Wed Jul 05 23:28:54 UTC 2023
|
PRIMARY | RxNorm | ||
|
DBSALT001277
Created by
admin on Wed Jul 05 23:28:54 UTC 2023 , Edited by admin on Wed Jul 05 23:28:54 UTC 2023
|
PRIMARY | |||
|
AA-69
Created by
admin on Wed Jul 05 23:28:54 UTC 2023 , Edited by admin on Wed Jul 05 23:28:54 UTC 2023
|
PRIMARY | |||
|
5581
Created by
admin on Wed Jul 05 23:28:54 UTC 2023 , Edited by admin on Wed Jul 05 23:28:54 UTC 2023
|
PRIMARY | |||
|
23690424
Created by
admin on Wed Jul 05 23:28:54 UTC 2023 , Edited by admin on Wed Jul 05 23:28:54 UTC 2023
|
PRIMARY | |||
|
SUB15315MIG
Created by
admin on Wed Jul 05 23:28:54 UTC 2023 , Edited by admin on Wed Jul 05 23:28:54 UTC 2023
|
PRIMARY | |||
|
C66723
Created by
admin on Wed Jul 05 23:28:54 UTC 2023 , Edited by admin on Wed Jul 05 23:28:54 UTC 2023
|
PRIMARY | |||
|
204-052-7
Created by
admin on Wed Jul 05 23:28:54 UTC 2023 , Edited by admin on Wed Jul 05 23:28:54 UTC 2023
|
PRIMARY | |||
|
48N6U1781G
Created by
admin on Wed Jul 05 23:28:54 UTC 2023 , Edited by admin on Wed Jul 05 23:28:54 UTC 2023
|
PRIMARY | |||
|
3039
Created by
admin on Wed Jul 05 23:28:54 UTC 2023 , Edited by admin on Wed Jul 05 23:28:54 UTC 2023
|
PRIMARY | |||
|
CHEMBL1200358
Created by
admin on Wed Jul 05 23:28:54 UTC 2023 , Edited by admin on Wed Jul 05 23:28:54 UTC 2023
|
PRIMARY | |||
|
100000078120
Created by
admin on Wed Jul 05 23:28:54 UTC 2023 , Edited by admin on Wed Jul 05 23:28:54 UTC 2023
|
PRIMARY | |||
|
114-70-5
Created by
admin on Wed Jul 05 23:28:54 UTC 2023 , Edited by admin on Wed Jul 05 23:28:54 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|